New schizophrenia shot matches pill in drug levels, early study shows

NCT ID NCT06315283

Completed Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Oct 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times

Summary

This study tested a new long-acting olanzapine injection (TV-44749) against the standard olanzapine pill in 153 adults with schizophrenia. The goal was to see if the shot delivers the same amount of medicine into the body as the pill. Researchers also checked for side effects. The study lasted about 21 weeks and is now complete.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Teva Investigational Site 15737

Marlton, New Jersey, 08053, United States
Teva Investigational Site 15738

Hollywood, Florida, 33024, United States
Teva Investigational Site 15739

Los Alamitos, California, 90720, United States
Teva Investigational Site 15740

Torrance, California, 90504, United States
Teva Investigational Site 15741

Atlanta, Georgia, 30331, United States
Teva Investigational Site 15742

Decatur, Georgia, 30030, United States
Teva Investigational Site 31326

Zamora, 49021, Spain
Teva Investigational Site 34310

Surrey, KT22 7AD, United Kingdom
Teva Investigational Site 60053

Zagreb, 10090, Croatia

Conditions

Explore the condition pages connected to this study.

SCHIZOPHRENIA